Compare AbbVie Inc (ABBV) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Consumer Staples Select Sector SPDR Fund trades at $84.39. The key difference: AbbVie Inc pays a 2.72% dividend while Consumer Staples Select Sector SPDR Fund pays none, and AbbVie Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABBV | XLP | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $90.00 |
52-Week Low | $184.85 | $75.61 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
XLP trades at $84.1, down 1.05% over the past day, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds a 100% buy rating from analysts and offers a 2.6% dividend yield, positioning it as a defensive play in consumer staples. Recent news highlights its role in portfolio diversification amid market volatility, with retail sales strength supporting the sector.
Outlook remains positive given analyst consensus and defensive characteristics, though risks include sector concentration and economic sensitivity. The ETF's low expense ratio and high yield appeal to income-focused investors, but competition from similar funds and macroeconomic pressures warrant monitoring for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
